Autism-Pipeline Review, H2 2015

Autism-Pipeline Review, H2 2015

  • Products Id :- GMDHC6942IDB
  • |
  • Pages: 131
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Autism-Pipeline Review, H2 2015


Global Markets Direct's, 'Autism-Pipeline Review, H2 2015', provides an overview of the Autism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Autism

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Autism and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Autism pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Autism

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Autism Overview 10

Therapeutics Development 11

Pipeline Products for Autism-Overview 11

Pipeline Products for Autism-Comparative Analysis 12

Autism-Therapeutics under Development by Companies 13

Autism-Therapeutics under Investigation by Universities/Institutes 15

Autism-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Autism-Products under Development by Companies 20

Autism-Products under Investigation by Universities/Institutes 22

Autism-Companies Involved in Therapeutics Development 23

Addex Therapeutics Ltd 23

BioCrea GmbH 24

BrainStorm Cell Therapeutics Inc. 25

Cellceutix Corporation 26

Confluence Pharmaceuticals LLC 27

Curemark, LLC 28

Egenix, Inc. 29

F. Hoffmann-La Roche Ltd. 30

Heptares Therapeutics Limited 31

Intra-Cellular Therapies, Inc. 32

MedDay 33

Merz Pharma GmbH & Co. KgaA 34

Mnemosyne Pharmaceuticals, Inc. 35

Omeros Corporation 36

Otsuka Holdings Co., Ltd. 37

Retrophin Inc. 38

Reviva Pharmaceuticals Inc. 39

Saniona AB 40

Sumitomo Dainippon Pharma Co., Ltd. 41

Autism-Therapeutics Assessment 42

Assessment by Monotherapy Products 42

Assessment by Combination Products 43

Assessment by Target 44

Assessment by Mechanism of Action 46

Assessment by Route of Administration 48

Assessment by Molecule Type 50

Drug Profiles 52

(dextromethorphan hydrobromide + quinidine sulfate)-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

acamprosate calcium-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

ADX-71441-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

ADX-88178-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

aripiprazole-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

aripiprazole-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

carbetocin-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

CM-AT-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

CN-2097-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Drug for Autism-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

HTL-14242-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

ITI-007-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

KM-391-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

lurasidone hydrochloride-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

MD-1103-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

memantine hydrochloride-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

oxytocin-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

RG-7314-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

RO-5285119-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

RP-5063-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Small Molecule to Modulate GABRA5 Receptor for CNS Disorders-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Small Molecule to Target GPR63 for Autism-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Small Molecules to Target Oxytocin for Autism and Anxiety Disorders-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Stem Cell Therapy for Neurodegenerative Disorders-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

suramin hexasodium-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

VU-0410120-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Autism-Recent Pipeline Updates 92

Autism-Dormant Projects 123

Autism-Discontinued Products 124

Autism-Product Development Milestones 125

Featured News & Press Releases 125

Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole 125

Jun 10, 2015: Clinical trial launched to assess safety and efficacy of autism drug treatment 125

May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism 126

Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment 127

Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism 127

Mar 13, 2013: Researchers Use Old Drug Treatment To Correct Autism Symptoms In Mouse Model 127

Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors 128

Appendix 130

Methodology 130

Coverage 130

Secondary Research 130

Primary Research 130

Expert Panel Validation 130

Contact Us 130

Disclaimer 131

List of Tables

Number of Products under Development for Autism, H2 2015 11

Number of Products under Development for Autism-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 14

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Late Stage Development, H2 2015 16

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Development, H2 2015 18

Comparative Analysis by Unknown Stage Development, H2 2015 19

Products under Development by Companies, H2 2015 20

Products under Development by Companies, H2 2015 (Contd..1) 21

Products under Investigation by Universities/Institutes, H2 2015 22

Autism-Pipeline by Addex Therapeutics Ltd, H2 2015 23

Autism-Pipeline by BioCrea GmbH, H2 2015 24

Autism-Pipeline by BrainStorm Cell Therapeutics Inc., H2 2015 25

Autism-Pipeline by Cellceutix Corporation, H2 2015 26

Autism-Pipeline by Confluence Pharmaceuticals LLC, H2 2015 27

Autism-Pipeline by Curemark, LLC, H2 2015 28

Autism-Pipeline by Egenix, Inc., H2 2015 29

Autism-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 30

Autism-Pipeline by Heptares Therapeutics Limited, H2 2015 31

Autism-Pipeline by Intra-Cellular Therapies, Inc., H2 2015 32

Autism-Pipeline by MedDay, H2 2015 33

Autism-Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2015 34

Autism-Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2015 35

Autism-Pipeline by Omeros Corporation, H2 2015 36

Autism-Pipeline by Otsuka Holdings Co., Ltd., H2 2015 37

Autism-Pipeline by Retrophin Inc., H2 2015 38

Autism-Pipeline by Reviva Pharmaceuticals Inc., H2 2015 39

Autism-Pipeline by Saniona AB, H2 2015 40

Autism-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 41

Assessment by Monotherapy Products, H2 2015 42

Assessment by Combination Products, H2 2015 43

Number of Products by Stage and Target, H2 2015 45

Number of Products by Stage and Mechanism of Action, H2 2015 47

Number of Products by Stage and Route of Administration, H2 2015 49

Number of Products by Stage and Molecule Type, H2 2015 51

Autism Therapeutics-Recent Pipeline Updates, H2 2015 92

Autism-Dormant Projects, H2 2015 123

Autism-Discontinued Products, H2 2015 124

List of Figures

Number of Products under Development for Autism, H2 2015 11

Number of Products under Development for Autism-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Late Stage Development, H2 2015 16

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Products, H2 2015 18

Assessment by Monotherapy Products, H2 2015 42

Number of Products by Top 10 Targets, H2 2015 44

Number of Products by Stage and Top 10 Targets, H2 2015 44

Number of Products by Top 10 Mechanism of Actions, H2 2015 46

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 46

Number of Products by Routes of Administration, H2 2015 48

Number of Products by Stage and Routes of Administration, H2 2015 48

Number of Products by Molecule Types, H2 2015 50

Number of Products by Stage and Molecule Types, H2 2015 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Addex Therapeutics Ltd

BioCrea GmbH

BrainStorm Cell Therapeutics Inc.

Cellceutix Corporation

Confluence Pharmaceuticals LLC

Curemark, LLC

Egenix, Inc.

F. Hoffmann-La Roche Ltd.

Heptares Therapeutics Limited

Intra-Cellular Therapies, Inc.


Merz Pharma GmbH & Co. KgaA

Mnemosyne Pharmaceuticals, Inc.

Omeros Corporation

Otsuka Holdings Co., Ltd.

Retrophin Inc.

Reviva Pharmaceuticals Inc.

Saniona AB

Sumitomo Dainippon Pharma Co., Ltd.

Autism Therapeutic Products under Development, Key Players in Autism Therapeutics, Autism Pipeline Overview, Autism Pipeline, Autism Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]